GM mosquitoes immune to all strains of dengue virus created

Image
Press Trust of India Washington
Last Updated : Jan 17 2020 | 4:15 PM IST

Scientists have for the first time genetically engineered mosquitoes that are resistant to all strains of the potentially deadly dengue virus.

Researchers at the University of California - San Diego, and Vanderbilt University in the US identified a broad spectrum human antibody for dengue suppression.

Described in the journal PLOS Pathogens, the research marks the first engineered approach in mosquitoes that targets the four known types of dengue, improving upon previous designs that addressed single strains.

They then designed the antibody "cargo" to be synthetically expressed in female Aedes aegypti mosquitoes, which spread the dengue virus.

"Once the female mosquito takes in blood, the antibody is activated and expressed -- that's the trigger," said UC San Diego Associate Professor Omar Akbari.

"The antibody is able to hinder the replication of the virus and prevent its dissemination throughout the mosquito, which then prevents its transmission to humans. It's a powerful approach," Akbari said in a statement.

The engineered mosquitoes could easily be paired with a dissemination system capable of spreading the antibody throughout wild disease-transmitting mosquito populations.

"It is fascinating that we now can transfer genes from the human immune system to confer immunity to mosquitoes.

"This work opens up a whole new field of biotechnology possibilities to interrupt mosquito-borne diseases of man," said James Crowe, director of the Vanderbilt Vaccine Center at Vanderbilt University.

According to the World Health Organization (WHO), dengue virus threatens millions of people in tropical and sub-tropical climates.

Severe dengue is a leading cause of serious illness and death among children in many Asian and Latin American countries.

Infecting those with compromised immune systems, dengue victims suffer flu-like symptoms, including severe fevers and rashes.

Serious cases can include life-threatening bleeding, the researchers said.

Currently no specific treatment exists, and thus prevention and control depend on measures that stop the spread of the virus, they said.

"This development means that in the foreseeable future there may be viable genetic approaches to controlling dengue virus in the field, which could limit human suffering and mortality," said Akbari.

His lab is now in the early stages of testing methods to simultaneously neutralise mosquitoes against dengue and a suite of other viruses such as Zika, yellow fever and chikungunya.

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Jan 17 2020 | 4:15 PM IST

Next Story